A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-003355-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the safety and tolerability (including an assessment of motor symptoms using the UPDRS) of open label 5-10 mg/day Aricept® in Parkinson's disease patients with dementia, who have completed the week 24 visit in the double-blind Aricept study E2020-E044-316.


Critère d'inclusion

  • Dementia associated with Parkinson's disease

Liens